These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 26445302)

  • 1. Trimetazidine Prevention of Contrast-Induced Nephropathy in Coronary Angiography.
    Liu W; Ming Q; Shen J; Wei Y; Li W; Chen W; Xu Y
    Am J Med Sci; 2015 Nov; 350(5):398-402. PubMed ID: 26445302
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Trimetazidine in the prevention of contrast-induced nephropathy in chronic kidney disease.
    Ibrahim TA; El-Mawardy RH; El-Serafy AS; El-Fekky EM
    Cardiovasc Revasc Med; 2017; 18(5):315-319. PubMed ID: 28532702
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Trimetazidine reduces contrast-induced nephropathy in patients with renal insufficiency undergoing coronary angiography and angioplasty: A systematic review and meta-analysis (PRISMA).
    Heshmatzadeh Behzadi A; Amoozgar B; Jain S; Velasco N; Zahid U; Abbasi H; Alasadi L; Prince MR
    Medicine (Baltimore); 2021 Mar; 100(10):e24603. PubMed ID: 33725824
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Coenzyme Q10 combined with trimetazidine in the prevention of contrast-induced nephropathy in patients with coronary heart disease complicated with renal dysfunction undergoing elective cardiac catheterization: a randomized control study and in vivo study.
    Chen F; Liu F; Lu J; Yang X; Xiao B; Jin Y; Zhang J
    Eur J Med Res; 2018 May; 23(1):23. PubMed ID: 29776437
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Trimetazidine can prevent the occurrence of contrast-induced nephropathy after percutaneous coronary intervention in elderly patients with renal insufficiency.
    Fu H; Zhang J; Zhang H; Zhang P; Fu X; Zeng Z; Zhang X; Li W; Yang S; Liu X; Fu N
    Perfusion; 2021 Sep; 36(6):603-609. PubMed ID: 32909511
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Trimetazidine in the prevention of contrast-induced nephropathy after coronary procedures.
    Onbasili AO; Yeniceriglu Y; Agaoglu P; Karul A; Tekten T; Akar H; Discigil G
    Heart; 2007 Jun; 93(6):698-702. PubMed ID: 17065180
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical effect of trimetazidine on prevention of contrast-induced nephropathy in patients with renal insufficiency: An updated systematic review and meta-analysis.
    Ye Z; Lu H; Su Q; Guo W; Dai W; Li H; Yang H; Li L
    Medicine (Baltimore); 2017 Mar; 96(9):e6059. PubMed ID: 28248861
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serum neutrophil gelatinase-associated lipocalin and cystatin C are early biomarkers of contrast-induced nephropathy after coronary angiography in patients with chronic kidney disease.
    Alharazy SM; Kong N; Saidin R; Gafor AH; Maskon O; Mohd M; Zakaria SZ
    Angiology; 2014 May; 65(5):436-42. PubMed ID: 23580616
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of Oral Nicorandil to Prevent Contrast-Induced Nephropathy in Patients with Chronic Renal Dysfunction Undergoing an Elective Coronary Procedure.
    Fan Z; Li Y; Ji H; Jian X
    Kidney Blood Press Res; 2019; 44(6):1372-1382. PubMed ID: 31639790
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Continuous intravenous infusion of nicorandil for 4 hours before and 24 hours after percutaneous coronary intervention protects against contrast-induced nephropathy in patients with poor renal function.
    Nawa T; Nishigaki K; Kinomura Y; Tanaka T; Yamada Y; Kawasaki M; Minatoguchi S
    Int J Cardiol; 2015 Sep; 195():228-34. PubMed ID: 26048382
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Trimetazidine Decreases Risk of Contrast-Induced Nephropathy in Patients With Chronic Kidney Disease: A Meta-Analysis of Randomized Controlled Trials.
    Nadkarni GN; Konstantinidis I; Patel A; Yacoub R; Kumbala D; Patel RA; Annapureddy N; Pakanati KC; Simoes PK; Javed F; Benjo AM
    J Cardiovasc Pharmacol Ther; 2015 Nov; 20(6):539-46. PubMed ID: 25715308
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of trimetazidine on preventing contrast-induced nephropathy in diabetic patients with renal insufficiency.
    Ye Z; Lu H; Su Q; Xian X; Li L
    Oncotarget; 2017 Nov; 8(60):102521-102530. PubMed ID: 29254267
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prevention of contrast-induced nephropathy with single bolus erythropoietin in patients with diabetic kidney disease: A randomized controlled trial.
    Shema-Didi L; Kristal B; Eizenberg S; Marzuq N; Sussan M; Feldman-Idov Y; Ofir P; Atar S
    Nephrology (Carlton); 2016 Apr; 21(4):295-300. PubMed ID: 26370061
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Trimetazidine in the prevention of contrast induced nephropathy after coronary angiogram.
    Rahman MM; Haque SS; Rokeya B; Siddique MA; Banerjee SK; Ahsan SA; Rahman F; Mahmood M; Ahmed K; Bhuiyan MM; Joarder AI; Debnath RC
    Mymensingh Med J; 2012 Apr; 21(2):292-9. PubMed ID: 22561774
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 20-Hour preprocedural hydration is not superior to 5-hour preprocedural hydration in the prevention of contrast-induced increases in serum creatinine and cystatin C.
    Torigoe K; Tamura A; Watanabe T; Kadota J
    Int J Cardiol; 2013 Sep; 167(5):2200-3. PubMed ID: 22717305
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intravenous N-acetylcysteine plus high-dose hydration versus high-dose hydration and standard hydration for the prevention of contrast-induced nephropathy: CASIS--a multicenter prospective controlled trial.
    Koc F; Ozdemir K; Kaya MG; Dogdu O; Vatankulu MA; Ayhan S; Erkorkmaz U; Sonmez O; Aygul MU; Kalay N; Kayrak M; Karabag T; Alihanoglu Y; Gunebakmaz O
    Int J Cardiol; 2012 Mar; 155(3):418-23. PubMed ID: 21106264
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prevention of Contrast-Induced Nephropathy by Central Venous Pressure-Guided Fluid Administration in Chronic Kidney Disease and Congestive Heart Failure Patients.
    Qian G; Fu Z; Guo J; Cao F; Chen Y
    JACC Cardiovasc Interv; 2016 Jan; 9(1):89-96. PubMed ID: 26685074
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Renoprotective effect of alprostadil in combination with statins in patients with mild to moderate renal failure undergoing coronary angiography.
    Liu WJ; Zhang BC; Guo R; Wei YD; Li WM; Xu YW
    Chin Med J (Engl); 2013; 126(18):3475-80. PubMed ID: 24034093
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of nebivolol in the prevention of contrast-induced nephropathy in patients with renal dysfunction.
    Avci E; Yeşil M; Bayata S; Postaci N; Arikan E; Cirit M
    Anadolu Kardiyol Derg; 2011 Nov; 11(7):613-7. PubMed ID: 21959875
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of N-acetylcysteine on cystatin C-based renal function after elective coronary angiography (ENABLE Study): a prospective, randomized trial.
    Kim BJ; Sung KC; Kim BS; Kang JH; Lee KB; Kim H; Lee MH
    Int J Cardiol; 2010 Feb; 138(3):239-45. PubMed ID: 18793808
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.